For following the competition: what moved in each program, several studies read as one move.
- iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819
- FT839
- Allogeneic iPSC-derived CD58KO Anti-MICA/MICB CAR-ADR-expressing T-cells FT836
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Fate Therapeutics to watchlistEvery Monday by email · turn it off any timePro · free during the beta